COMMUNIQUÉS West-GlobeNewswire

Fulgent Genetics and Columbia University Irving Medical Center Partner on Expanded Carrier Screening

03/01/2019 - 14:00

TEMPLE CITY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) and the Precision Genomics Laboratory (PGL), in collaboration with the Department of Obstetrics and Gynecology, at Columbia [...]

Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference

03/01/2019 - 14:00

BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 37 [...]

Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

03/01/2019 - 14:00

Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21 st Century Cures Act initiative CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. ( [...]

Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014

03/01/2019 - 14:00

Dose Escalation Trial in Patients with Solid Tumors CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of [...]

Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cell-Mediated Autoimmune Diseases

03/01/2019 - 14:00

Deerfield Management Company, Boxer Capital of Tavistock Group, Redmile Group and Cormorant Capital join founding investors Adage Capital, an undisclosed leading public equity healthcare investor and 5AM Ventures RADNOR [...]

AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer

03/01/2019 - 10:00

Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today announced that it has [...]

MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing

03/01/2019 - 09:01

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys B ioscience, Inc ., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has submitted a pre-IND ( [...]

Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

03/01/2019 - 08:00

Tara Rheault, PhD, MPH, named Vice President, R&D Operations and Global Project Management LONDON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage [...]

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic SteatoHepatitis (NASH)

03/01/2019 - 07:48

GENFIT AND LABCORP SIGN A LICENSING AGREEMENT TO EXPAND ACCESS TO AN INNOVATIVE DIAGNOSTIC ASSAY FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) Multi-Biomarker Test Will Provide the Clinical Research Community with a Non- [...]

GENFIT et LabCorp signent un accord de licence visant l'élargissement de l'accès à un test diagnostique innovant de la stéatohépatite non-alcoolique (NASH)

03/01/2019 - 07:48

GENFIT ET LABCORP SIGNENT UN ACCORD DE LICENCE VISANT L'ÉLARGISSEMENT DE L'ACCÈS À UN TEST DIAGNOSTIQUE INNOVANT DE LA STÉATOHÉPATITE NON-ALCOOLIQUE (NASH) Ce test, basé sur plusieurs biomarqueurs, fournira à la [...]

DBV Technologies Expands and Strengthens Leadership Team

03/01/2019 - 07:31

Montrouge, France, January 3, 2019 DBV Technologies Expands and Strengthens Leadership Team Key medical, manufacturing and regulatory leadership changes announced ahead of anticipated Viaskin Peanut BLA resubmission Dr [...]

DBV Technologies étend et renforce son équipe de management

03/01/2019 - 07:31

Montrouge, France, le 3 janvier (07h30 CET), 2019 DBV Technologies étend et renforce son équipe de management Des changements importants au niveau des directions médicales, des opérations pharmaceutiques, et du [...]

Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™

03/01/2019 - 07:30

Accelerates European Development of PSMA-Targeted Imaging Agent with Global Leader in Nuclear Medicine NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company [...]

Kiadis Pharma to present at Biotech Showcase 2019

03/01/2019 - 07:01

Kiadis Pharma to present at Biotech Showcase 2019 Amsterdam, The Netherlands, January 3, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage [...]

aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events

03/01/2019 - 01:37

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]

Mesa Labs Declares Quarterly Dividend

03/01/2019 - 01:00

Lakewood, Colo., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]

Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

03/01/2019 - 00:49

Company Release no. 01/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 January 2019 Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today [...]

Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study

02/01/2019 - 22:30

First patient enrolled in Phase 3 hip OA registration trial in late December 2018; trial expected to complete in 2020 Positive results from Phase 2 pharmacokinetics (PK) study of ZILRETTA in OA of shoulder and hip [...]

Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 22:30

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San [...]